Tempus: Bringing the power of data and artificial intelligence to healthcare

Integrating Data and AI in Healthcare

Tempus is at the forefront of healthcare innovation, committed to enhancing medical care through the deployment of cutting-edge technology solutions. By emphasizing the intersection of clinical practice and research, Tempus seeks to foster a productive cycle that significantly boosts patient outcomes. Utilizing their expertise in data analytics, artificial intelligence, and machine learning, Tempus is reshaping how healthcare is delivered. The company recognizes the vast potential in intertwining clinical care with research and aims to harness this synergy to drive advancements in medicine.

A primary goal of Tempus is to promote collaboration between healthcare providers and researchers. By connecting these two groups, Tempus believes that valuable insights can be uncovered, leading to the development of more effective treatments. Their technology facilitates the sharing of data and knowledge, creating a cooperative environment that accelerates medical discoveries.

Tempus strongly advocates for personalized medicine, acknowledging that each patient is unique, and their treatment should reflect that individuality. By analyzing extensive clinical and molecular data, Tempus strives to identify patterns and correlations that can guide healthcare providers in customizing treatments to meet each patient’s specific needs. This tailored approach not only improves patient outcomes but also reduces the likelihood of adverse effects and unnecessary procedures.

Moreover, Tempus emphasizes the importance of real-time data in clinical decision-making. They work to provide healthcare providers with timely and accurate information, enabling them to make informed decisions that enhance patient care. Through advanced technologies, Tempus facilitates the real-time collection and analysis of data, ensuring that healthcare professionals have access to the latest information when making critical choices.

Transforming Cancer Care

Tempus delivers a comprehensive genomic profiling service that encompasses hereditary testing, minimal residual disease monitoring, and therapy selection. This all-in-one platform addresses a broad spectrum of cancer testing needs, supported by a vast multimodal database that makes precision medicine a reality for patients globally.

Pioneering Precision Oncology

The AI-driven solutions from Tempus have revolutionized the detection of biomarkers and the identification of actionable variants associated with targeted therapies. In a recent analysis involving metastatic cancer patients, 9% exhibited unique actionable variations found through liquid biopsies that were not detected in solid tumors alone.

Enhancing Radiology Insights

Tempus also generates actionable insights from radiology images, assisting providers in making informed diagnostic and treatment choices. The company offers automated tools for quantification, tracking, and reporting, specifically designed to help oncologists monitor disease progression efficiently.

Accelerating Therapy Development

By providing access to real-world multimodal data—from DNA, RNA, to whole slide pathology images—Tempus advances the discovery and innovation in therapy development. Their Lens platform enables researchers to analyze a collection of over 6 million de-identified research records, revealing crucial insights that can propel innovation and enhance patient outcomes.

Streamlining Companion Diagnostics

Tempus adopts a data-driven approach to companion diagnostics (CDx) partnerships, utilizing a broad-panel platform trusted by thousands of oncologists. This strategy streamlines CDx development and approval processes, reducing time and complexity while improving the chances of success.

Meet Eric Lefkofsky, Founder & CEO

Eric Lefkofsky is the visionary behind Tempus. As a successful entrepreneur and investor, he has co- founded several companies, including Groupon, Echo Global Logistics, InnerWorkings, and Pathos AI.

Lefkofsky is also the co-chair of the Lefkofsky Family Foundation and serves on the board of directors of Northwestern Medicine.

“Through our scientific publications and research projects, we are accelerating and transforming personalized patient care.”